CytoDyn Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' (Deficit) Equity

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) shares in Thousands, $ in Thousands	Preferred Stock	Common Stock Registered Direct Offering [Member]	Common Stock Public Warrant Tender Offering [Member]	Common Stock Private Warrant Exchange [Member]	Common Stock Private Equity Offering	Common Stock	Treasury Stock Public Warrant Tender Offering [Member]	Treasury Stock	Additional Paid-in Capital Registered Direct Offering [Member]	Additional Paid-in Capital Public Warrant Tender Offering [Member]	Additional Paid-in Capital Private Warrant Exchange [Member]	Additional Paid-in Capital Private Equity Offering	Additional Paid-in Capital	Accumulated Deficit	Registered Direct Offering [Member]	Public Warrant Tender Offering [Member]	Private Warrant Exchange [Member]	Private Equity Offering	Total
Beginning balance at May. 31, 2019						$ 330							$ 225,177	$ (234,420)					$ (8,913)
Beginning balance, shares at May. 31, 2019	95					329,555		159
Issuance of stock for convertible note repayment, value						$ 23							10,799						10,822
Issuance of stock for convertible note repayment, shares						22,967
Note conversion and extension fees, value						$ 8							3,891						3,899
Note conversion and extension fees, shares						8,232
Stock issued via offering, tender or placement, value		$ 39	$ 45	$ 20					$ 12,627	$ 11,855	$ 6,001		13,409		$ 12,666	$ 11,900	$ 6,021		13,409
Stock issued via offering, tender or placement, shares	14	38,856	45,376	20,529
Warrant exercises, value						$ 42							20,458						20,500
Warrant exercises, shares						42,024
Relative fair market value associated with warrants exercised													11,949						11,949
Inducement interest expense										2,713						2,713
Inducement interest expense related to private warrant exchange, value													20,724						20,724
Dividends accrued and paid on preferred stock, value														(945)					(945)
Legal fees in connection with equity offerings													(16)						(16)
Stock issued for services, value						$ 3							(3)
Stock issued for services, shares						2,620
Stock issued for bonuses and tendered for income tax, value													154						154
Stock issued for bonuses and tendered for income tax, shares						380		127
Stock option exercises, value						$ 9							5,594						5,603
Stock option exercises, shares						8,723
Stock-based compensation													6,548						6,548
Issuance of legal settlement, warrants, value													22,500						22,500
Offering costs, stock and warrants									$ (378)	(1,059)	(197)		(437)		$ (378)	(1,059)	$ (197)		(437)
Exercise of option to repurchase common stock, value													(8)						(8)
Net loss														(139,936)					(139,936)
Ending balance at May. 31, 2020						$ 519							372,301	(375,301)					(2,481)
Ending balance, shares at May. 31, 2020	109					519,262		286
Issuance of stock for convertible note repayment, value						$ 24							96,914						96,938
Issuance of stock for convertible note repayment, shares						24,154
Stock issued via offering, tender or placement, value					$ 1					$ 828		$ 999				$ 828		$ 1,000
Stock issued via offering, tender or placement, shares			323		667		157										35,800	8,900
Warrant exercises, value				$ 37		$ 38					17,519		18,611				$ 17,556		$ 18,649
Warrant exercises, shares				37,054		37,941													26,700
Inducement interest expense related to private warrant exchange, value													13,922						$ 13,922
Dividends accrued and paid on preferred stock, value														(1,909)					(1,909)
Stock option exercises, value						$ 3							1,835						1,838
Stock option exercises, shares						2,591
Stock-based compensation													9,601						$ 9,601
Issuance of legal settlement, warrants, value						$ 4							(4)
Issuance of legal settlement, warrants, shares						4,000
Conversion of preferred stock to common stock, shares	(13)					131
Offering costs, stock and warrants											(495)						(495)
Issuance of common stock upon vesting of stock based compensation awards, shares																			200
Net loss														(176,465)					$ (176,465)
Ending balance at May. 31, 2021						$ 626							532,031	(553,675)					(21,018)
Ending balance, shares at May. 31, 2021	96					626,123		443
Issuance of stock for convertible note repayment, value						$ 37							68,344						$ 68,381
Issuance of stock for convertible note repayment, shares						37,110
Stock issued via offering, tender or placement, value					$ 38							$ 46,473						$ 46,511
Stock issued via offering, tender or placement, shares					38,035														7,900
Warrant exercises, value				$ 8		$ 2					$ 5,382		1,034				$ 5,390		$ 1,036
Warrant exercises, shares				7,920		1,642													1,400
Inducement interest expense related to private warrant exchange, value						$ 2							6,689						$ 6,691
Inducement interest expense related to private warrant exchange, shares						2,293
Dividends accrued and paid on preferred stock, value						$ 1							305	(1,636)					(1,330)
Dividends accrued and paid on preferred stock, shares						613
Stock issued for bonuses and tendered for income tax, value						$ 2							666						668
Stock issued for bonuses and tendered for income tax, shares						2,582
Stock option exercises, value						$ 1							389						$ 390
Stock option exercises, shares						510													500
Stock-based compensation													5,571						$ 5,571
Issuance of legal settlement, warrants, value													2,863						2,863
Conversion of preferred stock to common stock						$ 3							(3)
Conversion of preferred stock to common stock, shares	(61)					3,200
Finance charges related to warrant issuance for surety bond backstop agreement													6,585						6,585
Offering costs, stock and warrants													(5,316)						(5,316)
Net loss														(210,820)					(210,820)
Ending balance at May. 31, 2022						$ 720							$ 671,013	$ (766,131)					$ (94,398)
Ending balance, shares at May. 31, 2022	35					720,028		443